Celldex Therapeutics (CLDX) News Today $20.35 -0.02 (-0.10%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.34 -0.01 (-0.02%) As of 05/23/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growthMay 24 at 4:56 PM | investing.comTwinbeech Capital LP Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Twinbeech Capital LP lowered its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 34,558 shares of the biopharmaceutical company's stock after selling 105,944 sharesMay 24 at 4:53 AM | marketbeat.comDeutsche Bank AG Acquires 82,042 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Deutsche Bank AG lifted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 207.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 121,501 shares of the biopharmaceuticaMay 23 at 3:35 AM | marketbeat.comWoodline Partners LP Cuts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Woodline Partners LP trimmed its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 14.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,014,015 shares of the biopharmaceutical comMay 22 at 6:18 AM | marketbeat.comVestal Point Capital LP Acquires Shares of 305,000 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Vestal Point Capital LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 305,000 shares of the biopharmaceMay 21, 2025 | marketbeat.comRafferty Asset Management LLC Acquires 61,464 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Rafferty Asset Management LLC boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 67.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 152,454 shareMay 21, 2025 | marketbeat.comBNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)BNP Paribas Financial Markets grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 122.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 62,631 shares of the biopharmaceutical company's stock after buying an additional 34,450 shareMay 21, 2025 | marketbeat.com29,480 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by Tema Etfs LLCTema Etfs LLC purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 29,480 shares of the biopharmaceutical company's stock, vMay 20, 2025 | marketbeat.com192,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by TFG Asset Management GP LtdTFG Asset Management GP Ltd purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 192,000 shares of the biopharmaceutical company's stMay 20, 2025 | marketbeat.comSphera Funds Management LTD. Has $11.98 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Sphera Funds Management LTD. increased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 474,103 shares oMay 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Acquires 847,264 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Point72 Asset Management L.P. lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 50.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,515,972 shares of the biopharmaceutiMay 18, 2025 | marketbeat.comPolar Asset Management Partners Inc. Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Polar Asset Management Partners Inc. lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 1,318.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 137,550 shares of the biopharmaceutical company's stock after purcMay 18, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Northern Trust Corp boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 6.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 597,605 shares of the biopharmaceutical company's stock after purchasingMay 18, 2025 | marketbeat.comPolar Capital Holdings Plc Cuts Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Polar Capital Holdings Plc lowered its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 42.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,565,831 shares of the biopharmaceutical company's stock aftMay 17, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 306,777 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)D. E. Shaw & Co. Inc. lessened its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 37.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 518,340 shares of the biopharmaceutical company's stock after selling 306,777 sharesMay 16, 2025 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for CLDX EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2029 earnings estimates for Celldex Therapeutics in a research report issued on Friday, May 9th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical comMay 14, 2025 | marketbeat.com2 'Strong Buy' Biotech Growth Stocks With Over 200% Upside PotentialMay 12, 2025 | msn.comCelldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy RatingMay 12, 2025 | tipranks.comCubist Systematic Strategies LLC Invests $3.91 Million in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Cubist Systematic Strategies LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 154,512 shares of the biopharmaceutical company'sMay 12, 2025 | marketbeat.comFirst Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)First Trust Advisors LP decreased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 50.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,372 shares of the biopharmaceutical company's stock after selling 19,071 shareMay 12, 2025 | marketbeat.comCelldex Therapeutics Q1 2025 Earnings: EPS of ($0. ...May 11, 2025 | gurufocus.comAlgert Global LLC Purchases 49,354 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Algert Global LLC increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 89.8% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 104,337 shares of the biopharmaceutical company's stock after buying an additional 49,3May 10, 2025 | marketbeat.comTudor Investment Corp ET AL Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Tudor Investment Corp ET AL purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 32,545 shares of theMay 10, 2025 | marketbeat.comCelldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comDeep Track Capital LP Buys New Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Deep Track Capital LP purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,540,132 shares of the biopharmaceuticMay 9, 2025 | marketbeat.comDecoding Celldex Therapeutics Inc (CLDX): A Strategic SWOT InsightMay 9, 2025 | gurufocus.comCelldex Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.comHC Wainwright Reiterates "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX)HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday.May 8, 2025 | marketbeat.comCrestline Management LP Grows Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Crestline Management LP raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 114.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 295,354 shares of the biopharmaceutical company's stock aMay 8, 2025 | marketbeat.comCelldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock NewsMay 6, 2025 | gurufocus.comCelldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat DiseaseMay 5, 2025 | globenewswire.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has givMay 4, 2025 | marketbeat.comNovo Holdings A S Buys 36,337 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Novo Holdings A S boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,000,000 shares of the biopharmaceutical company's stock afteMay 3, 2025 | marketbeat.comNebula Research & Development LLC Acquires Shares of 14,027 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Nebula Research & Development LLC bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 14,027 shares of the biopharmaceutMay 3, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - What's Next?Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - Still a Buy?April 30, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Now Covered by Canaccord Genuity GroupCanaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday. They set a "buy" rating and a $64.00 price objective for the company.April 30, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD increased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,557,136 shares of the biopharmaApril 30, 2025 | marketbeat.comCelldex Therapeutics (CLDX) Expected to Announce Earnings on MondayCelldex Therapeutics (NASDAQ:CLDX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-celldex-therapeutics-inc-stock/)April 30, 2025 | marketbeat.comBarclays PLC Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Barclays PLC grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 9.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 142,914 shares of the biopharmaceutical company's stock after buyinApril 30, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Decreases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)T. Rowe Price Investment Management Inc. cut its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,697,498 shares of the biopharApril 29, 2025 | marketbeat.com3CLDX : Analyst Expectations For Celldex Therapeutics's FutureApril 29, 2025 | benzinga.comGuggenheim Capital LLC Buys Shares of 23,797 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Guggenheim Capital LLC purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 23,797 shares of the biopharmaceutical coApril 28, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by XTX Topco LtdXTX Topco Ltd reduced its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,256 shares of the biopharmaceutical company's stock after selling 34,661 sApril 28, 2025 | marketbeat.com15,800 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by NatixisNatixis purchased a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,800 shares of the biopharmaceutical company's stock, valued at approximatelApril 27, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Canada Pension Plan Investment BoardCanada Pension Plan Investment Board trimmed its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 42.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,000 shares of the biopharmApril 27, 2025 | marketbeat.comJump Financial LLC Acquires Shares of 16,513 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Jump Financial LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 16,513 shares of the biopharmaceutical company's stock, valued at approxApril 27, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)JPMorgan Chase & Co. lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 103.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,545 shares of the biopharmaceutical company's stock aApril 26, 2025 | marketbeat.comRenaissance Technologies LLC Makes New $3.45 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Renaissance Technologies LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 136,588 shares of the biopharmaceuticApril 25, 2025 | marketbeat.comSilverarc Capital Management LLC Acquires 119,560 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Silverarc Capital Management LLC grew its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 82.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 264,560 shares of the biopharmaceutical company's stock afterApril 24, 2025 | marketbeat.comEversept Partners LP Increases Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Eversept Partners LP grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 27.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 719,836 shares of the biopharmaceutical company's stock after purchasing an additional 154,934April 24, 2025 | marketbeat.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼1.660.75▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼105▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ionis Pharmaceuticals News Alkermes News BioCryst Pharmaceuticals News Ligand Pharmaceuticals News Amicus Therapeutics News MannKind News Novavax News Dynavax Technologies News Innoviva News OPKO Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDX Stock Free CLDX Stock Alerts